{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:27:18Z","timestamp":1785904038008,"version":"3.56.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T00:00:00Z","timestamp":1619568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Beh\u00e7et's disease (BD) is a chronic, relapsing inflammatory, multisystem disease of unknown etiology. The disease has a wide clinical spectrum of mucocutaneous lesions and ocular, vascular, articular, neurologic, gastrointestinal and cardiac involvement. Although the number of effective drugs used in the disease's treatment has increased in recent years, BD is still associated with severe morbidity because of mainly mucocutaneous, articular and ocular symptoms and an increased mortality because of large vessel, neurological, gastrointestinal and cardiac involvement. Many factors are associated with a more serious course, such as male gender and a younger age of onset. While the severity of the disease is more pronounced in the first years of the disease, it decreases in most patients after the age of forties. The primary goal of treatment should be the prevention of irreversible organ damage. Therefore, early diagnosis and appropriate treatment and close follow-up are mandatory to reduce the morbidity and mortality of the disease. Treatment varies depending on the organ involved and the severity of the involvement. For all these reasons, the treatment should be personalized and arranged with a multidisciplinary approach according to the organs involved. Treatment is mainly based on suppression of the inflammatory attacks of the disease using local and systemic immunomodulatory and immunosuppressive drugs. In this review, based on the mainly controlled studies and personal experience in clinical practice and basic research in this field, we propose a stepwise, symptom-based, algorithmic approach for the management of BD with a holistic perspective.<\/jats:p>","DOI":"10.3389\/fmed.2021.624795","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T04:30:32Z","timestamp":1619584232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Treatment of Beh\u00e7et's Disease: An Algorithmic Multidisciplinary Approach"],"prefix":"10.3389","volume":"8","author":[{"given":"Erkan","family":"Alpsoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Leccese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iii101","DOI":"10.1093\/rheumatology\/kez626","article-title":"Beh\u00e7et: the syndrome","volume":"59","author":"Bettiol","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1365-2230.2005.01846.x","article-title":"CTLA-4 gene 49A\/G polymorphism in Turkish patients with Beh\u00e7et's disease","volume":"30","author":"Sallakci","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/1346-8138.13381","article-title":"Beh\u00e7et's disease: a comprehensive review with a focus on epidemiology, etiology and clinical features, and management of mucocutaneous lesions","volume":"43","author":"Alpsoy","year":"2016","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fimmu.2019.01067","article-title":"Beh\u00e7et's disease: an overview of etiopathogenesis","volume":"10","author":"Leccese","year":"2019","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000068888","article-title":"Serum of patients with Beh\u00e7et's disease induces classical (pro-inflammatory) activation of human macrophages in vitro","volume":"206","author":"Alpsoy","year":"2003","journal-title":"Dermatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s11739-019-02154-9","article-title":"Beh\u00e7et's syndrome: focus on pathogenetic background, clinical phenotypes and specific treatments","volume":"14","author":"Emmi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"B7","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Beh\u00e7et's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3349\/ymj.2007.48.4.573","article-title":"Mucocutaneous lesions of Beh\u00e7et's disease","volume":"48","author":"Alpsoy","year":"2007","journal-title":"Yonsei Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1046\/j.1365-4362.1998.00401.x","article-title":"A randomized, controlled and blinded study of papulopustular lesions in Turkish Behcet's patients","volume":"37","author":"Alpsoy","year":"1998","journal-title":"Int J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1365-2133.2007.08116.x","article-title":"Clinical features and natural course of Beh\u00e7et's disease in 661 cases: a multicentre study","volume":"157","author":"Alpsoy","year":"2007","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.2165\/11641370-000000000-00000","article-title":"Behcet's syndrome","volume":"72","author":"Dalvi","year":"2012","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/ard.60.11.1074","article-title":"Papulopustular skin lesions are seen more frequently in patients with Beh\u00e7et's syndrome who have arthritis: a controlled and masked study","volume":"60","author":"Diri","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/09273948.2015.1094095","article-title":"Ocular Beh\u00e7et's disease: changing patterns over time, complications and long-term visual prognosis","volume":"25","author":"Accorinti","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.3109\/09273948.2014.981547","article-title":"A major review: current aspects of ocular Beh\u00e7et's disease in Japan","volume":"23","author":"Namba","year":"2015","journal-title":"Ocul Immunol Inflamm"},{"key":"B16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/978-3-540-75387-2_66","article-title":"Behcet' s disease","volume-title":"Intraocular Inflammation","author":"Ohno","year":"2016"},{"key":"B17","first-page":"56","article-title":"(editors) Treatment algorithm of ocular Behcet's disease","volume-title":"Clinical Practice Guidelines for Behcet's Disease 2020","author":"Mizuki","year":"2020"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11739-018-1991-y","article-title":"Vascular Beh\u00e7et's syndrome: an update","volume":"14","author":"Emmi","year":"2019","journal-title":"Intern Emerg Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of Neuro-Beh\u00e7et's disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","article-title":"The 2nd edition of consensus statements for the diagnosis and management of intestinal Beh\u00e7et's disease: indication of anti-TNF\u03b1 monoclonal antibodies","volume":"49","author":"Hisamatsu","year":"2014","journal-title":"J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1007\/s00296-015-3310-5","article-title":"The natural course and factors affecting severity of Beh\u00e7et's disease: a single-center cohort of 368 patients","volume":"35","author":"Ugurlu","year":"2015","journal-title":"Rheumatol Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-4362.1997.tb03133.x","article-title":"Topical cyclosporine-A for treatment of oral ulcers of Beh\u00e7et's syndrome","volume":"36","author":"Ergun","year":"1997","journal-title":"Int J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/rheumatology\/30.5.395-a","article-title":"Inefficacy of topical alpha interferon in the treatment of oral ulcers of Beh\u00e7et's syndrome: a randomized, double blind trial","volume":"30","author":"Hamuryudan","year":"1991","journal-title":"Br J Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/rheumatology\/kep237","article-title":"Low-dose natural human interferon-alpha lozenges in the treatment of Beh\u00e7et's syndrome","volume":"48","author":"Kili\u00e7","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"B27","unstructured":"Pentoxifylline Gel for Oral Ulcers in Patients with Beh\u00e7et's Syndrome [abstract]\n            HatemiG\n            YurttasB\n            KutlubayZ\n            CoteT\n            DerkuntS\n            YaziciY\n          Arthritis Rheumatol712019"},{"key":"B28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000182257","article-title":"Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Beh\u00e7et's disease","volume":"218","author":"Kose","year":"2009","journal-title":"Dermatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1756-185X.2010.01531.x","article-title":"Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial","volume":"13","author":"Chams-Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archderm.135.5.529","article-title":"The use of sucralfate suspension in the treatment of oral and genital ulcerations of Beh\u00e7et's disease: a randomised, placebo-controlled and double-blind study","volume":"135","author":"Alpsoy","year":"1999","journal-title":"Arch Dermatol"},{"key":"B31","first-page":"75","article-title":"Comparing the effect of phenytoin syrup and triamcinolone acetonide ointment on aphthous ulcers in patients with Behcet's syndrome","volume":"14","author":"Fani","year":"2012","journal-title":"Iran Red Crescent Med J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/rheumatology\/27.4.300","article-title":"Treatment with acyclovir does not affect orogenital ulcers in Beh\u00e7et's syndrome: a randomized double-blind trial","volume":"27","author":"Davies","year":"1988","journal-title":"Br J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Beh\u00e7et's syndrome\u2013a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"B35","first-page":"493","article-title":"Ineficacy of azapropazone in the acute arthritis of Beh\u00e7et's syndrome: a randomized, double blind, placebo controlled study","volume":"13","author":"Moral","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"B36","first-page":"S320","article-title":"Pulse cyclophosphamide (PCP) for ocular lesions of Beh\u00e7et's disease: double blind crossover study","volume":"42","author":"Davatchi","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B37","first-page":"399","article-title":"A double blind study of colchicine in Behcet's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"B39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Beh\u00e7et's disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Mod Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000246336","article-title":"Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease","volume":"192","author":"Calguneri","year":"1996","journal-title":"Dermatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","article-title":"A double-blind trial of depot corticosteroids in Beh\u00e7et's syndrome","volume":"45","author":"Mat","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"20","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"B43","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et's syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"B44","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/000348949110000607","article-title":"Effect of cyclosporine A on the hearing loss in Beh\u00e7et's disease","volume":"100","author":"Elidan","year":"1991","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B45","first-page":"603","article-title":"Low-dose cyclosporin in Beh\u00e7et's disease: follow-up controlled study with emphasis on extraocular manifestations and neuro-Beh\u00e7et's disease","volume-title":"Beh\u00e7et's Disease: Basic and Clinical Aspects","author":"Assaad-Khalil","year":"1991"},{"key":"B46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"B48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"key":"B49","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alpha-2a in the treatment of Beh\u00e7et disease: a randomized, placebo-controlled and double blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/annrheumdis-2014-205571","article-title":"Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet's disease with upregulation of circulating regulatory T cells and reduction of Th17","volume":"74","author":"Lightman","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/annrheumdis-2016-eular.2780","article-title":"Interferon alpha2a versus cyclosporin A for the treatment of severe ocular Beh\u00e7et's disease-A prospective, randomized, single blind, national multi center trial (INCYTOB)","volume":"75","author":"K\u00f6tter","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B53","first-page":"e68","article-title":"The therapeutic role of isotretinoin in the management of Beh\u00e7et's disease: a single-blinded, controlled therapeutic study","volume":"12","author":"Sharquie","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"B54","first-page":"291","article-title":"The therapeutic and immunological effects of levamisole in recurrent oral ulcers and Beh\u00e7et's syndrome","volume-title":"Beh\u00e7et's Syndrome: Clinical and Immunological Features","author":"Lehner","year":"1979"},{"key":"B55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00126839-200304010-00002","article-title":"Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Beh\u00e7et's disease: a randomised, double-blind, placebo-controlled study","volume":"4","author":"Matsuda","year":"2003","journal-title":"Drugs R D."},{"key":"B56","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1346-8138.2006.00128.x","article-title":"Oral zinc sulfate in the treatment of Behcet's disease: a double blind cross-over study","volume":"33","author":"Sharquie","year":"2006","journal-title":"J Dermatol"},{"key":"B60","first-page":"532","article-title":"Beh\u00e7et's disease: treatment of mucocutaneous lesions","volume":"23","author":"Alpsoy","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","article-title":"Management of skin, mucosa and joint involvement of Beh\u00e7et's syndrome: a systematic review for update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"48","author":"Leccese","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B62","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00403-009-0990-2","article-title":"Beh\u00e7et's disease: an algorithmic approach to its treatment","volume":"301","author":"Alpsoy","year":"2009","journal-title":"Arch Dermatol Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2019-215437","article-title":"Real-world effectiveness of apremilast in multirefractory mucosal involvement of Beh\u00e7et's disease","volume":"78","author":"Lopalco","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et's syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/annrheumdis-2020-217108","article-title":"Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Beh\u00e7et's phenotype: a multicentre study","volume":"79","author":"Fagni","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Beh\u00e7et's disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":"The effect of prophylactic penicillin treatment on the course of arthritis of Beh\u00e7et's disease: a randomised clinical trial","volume":"39","author":"Calguneri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"B68","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0190-9622(94)70226-8","article-title":"Interferon therapy for Beh\u00e7et's disease","volume":"31","author":"Alpsoy","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"B69","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Beh\u00e7et's syndrome","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh\u00e7et disease: results of an open 4-center trial","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"B71","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Beh\u00e7et's disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/ or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long-term outcome of ustekinumab therapy for Beh\u00e7et's disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10787-020-00697-4","article-title":"Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Beh\u00e7et's syndrome","volume":"28","author":"Silvestri","year":"2020","journal-title":"Inflammopharmacology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/09273948.2017.1391297","article-title":"Ten-Year retention rate of infliximab in patients with Beh\u00e7et's disease-related uveitis","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1080\/09273948.2018.1511810","article-title":"The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Beh\u00e7et's disease","volume":"28","author":"Fabiani","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et's syndrome as a model of thrombo-inflammation: the role of neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/CIRCULATIONAHA.115.017738","article-title":"Neutrophil activation promotes fibrinogen oxidation and thrombus formation in Beh\u00e7et disease","volume":"133","author":"Becatti","year":"2016","journal-title":"Circulation"},{"key":"B81","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/CIRCRESAHA.120.317789","article-title":"Butyrate rich diets improve redox status and fibrin lysis in Beh\u00e7et's syndrome","volume":"128","author":"Emmi","year":"2021","journal-title":"Circ Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.3389\/fimmu.2019.02877","article-title":"Stem-cell-derived circulating progenitors dysfunction in Beh\u00e7et's syndrome patients correlates with oxidative stress","volume":"10","author":"Emmi","year":"2019","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clim.2018.08.004","article-title":"Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: a multicenter observational study of 18 patients","volume":"197","author":"Desbois","year":"2018","journal-title":"Clin Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et's syndrome: a retrospective study of seventy patients with vascular involvement","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.24393","article-title":"Cerebral venous thrombosis in Beh\u00e7et's disease","volume":"61","author":"Saadoun","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B86","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.semarthrit.2015.06.008","article-title":"Pulmonary artery involvement in Beh\u00e7et?s syndrome: effects of anti-Tnf treatment","volume":"45","author":"Hamuryudan","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B87","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MD.0b013e318242ff37","article-title":"Pulmonary artery involvement and associated lung disease in Beh\u00e7et disease: a series of 47 patients","volume":"91","author":"Seyahi","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11739-018-1863-5","article-title":"Hemoptysis in Beh\u00e7et's syndrome: from bedside to bench?","volume":"13","author":"Rossi","year":"2018","journal-title":"Intern Emerg Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11739-018-1817-y","article-title":"Transcatheter embolotherapy of pulmonary artery aneurysms as emergency treatment of hemoptysis in Behcet patients: experience of a referral center and a review of the literature","volume":"13","author":"Voiriot","year":"2018","journal-title":"Intern Emerg Med"},{"key":"B90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/rheumatology\/33.1.48","article-title":"Pulmonary arterial aneurysms in Beh\u00e7et's syndrome: a report of 24 cases","volume":"33","author":"Hamuryudan","year":"1994","journal-title":"Br J Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.amjmed.2004.05.027","article-title":"Pulmonary artery aneurysms in Beh\u00e7et syndrome","volume":"117","author":"Hamuryudan","year":"2004","journal-title":"Am J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/art.38351","article-title":"Long-term outcome of neuro-Beh\u00e7et's disease","volume":"66","author":"Noel","year":"2014","journal-title":"Arthritis Rheum"},{"key":"B93","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Behcet's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Beh\u00e7et's syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheum Oxford"},{"key":"B96","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jns.2015.01.005","article-title":"Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behcet's disease","volume":"349","author":"Hirohata","year":"2015","journal-title":"J Neurol Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/qjmed\/hcq125","article-title":"D. Interferon-\u03b1 treatment for acute myelitis and intestinal involvement in severe Beh\u00e7et's disease","volume":"103","author":"Monastirli","year":"2010","journal-title":"QJM"},{"key":"B98","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-alpha 2a treatment of neuro-Behcet disease","volume":"21","author":"Nichols","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"B99","first-page":"S64","article-title":"Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro- Behcet's disease with parenchymal involvement: presentation of four cases","volume":"29","author":"Shugaiv","year":"2011","journal-title":"Clin Exp Rheumatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","article-title":"Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et","volume":"44","author":"Addimanda","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/01.STR.0000117571.76197.26","article-title":"Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)","volume":"35","author":"Ferro","year":"2004","journal-title":"Stroke"},{"key":"B103","doi-asserted-by":"publisher","first-page":"318","DOI":"10.5217\/ir.2017.15.3.318","article-title":"Treatment and outcomes: medical and surgical treatment for intestinal Beh\u00e7et's disease","volume":"15","author":"Hisamatsu","year":"2017","journal-title":"Intest Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11739-019-02035-1","article-title":"Update on the treatment of Beh\u00e7et's syndrome","volume":"14","author":"Esatoglu","year":"2019"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3904\/kjim.2017.377","article-title":"Updated treatment strategies for intestinal Beh\u00e7et's disease","volume":"33","author":"Park","year":"2018","journal-title":"Korean J Intern Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3109\/s10165-010-0370-y","article-title":"Efficacy of combination therapy of anti-TNF-\u03b1 antibody infliximab and methotrexate in refractory entero-Beh\u00e7et's disease","volume":"21","author":"Iwata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1345\/aph.1D524","article-title":"Treatment of recurrent perforating intestinal ulcers with thalidomide in Beh\u00e7et's disease","volume":"38","author":"Sayarlioglu","year":"2004","journal-title":"Ann Pharmacother"},{"key":"B108","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ibd.20317","article-title":"Thalidomide for treatment of intestinal involvement of juvenile-onset Beh\u00e7et disease","volume":"14","author":"Yasui","year":"2008","journal-title":"Inflamm Bowel Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.624795\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T04:31:03Z","timestamp":1619584263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.624795\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,28]]},"references-count":108,"alternative-id":["10.3389\/fmed.2021.624795"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.624795","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,28]]},"article-number":"624795"}}